Pejmon Pashai
Associate | Washington, D.C.
Pejmon Pashai

Pejmon Pashai focuses his practice on intellectual property litigation for innovative biotechnology and pharmaceutical companies, primarily patent and trade secret litigation for gene therapies, novel botulinum toxin type A products, small molecules, and drug delivery devices. Mr. Pashai has extensive experience in cases arising under the Hatch-Waxman Act and pre-BPCIA diligence. He is involved in all aspects of litigation, including pre-litigation due diligence, fact discovery, expert discovery, fact witness and expert depositions, motions practice, and trial preparation. Mr. Pashai has also published and presented at international conferences on his research in the field of arterial chemoreception.

Prior to joining Dechert, Mr. Pashai was an attorney in the Washington, D.C. office of an international law firm.

  • Major brand pharmaceutical companies in litigation arising under the Hatch-Waxman Act against eight generic drug manufacturers. 
  • Multiple brand pharmaceutical companies on pre-litigation due diligence and Orange Book listing.  

Includes matters handled prior to joining the firm. 

Services Industries
    • University of Maryland, Baltimore County, B.S., Biological Sciences, B.A. Philosophy, 2012
    • University of Maryland, Francis King Carey School of Law, J.D., 2017, cum laude, Moot Court Team, Member of the Journal of Health Care Law and Policy
    • District of Columbia
    • Maryland
    • English
    • Farsi